Download PDF
Exp Clin Endocrinol Diabetes 2021; 129(03): 146-156
DOI: 10.1055/a-1310-7900
Review

Clinical Implications of the New WHO Classification 2017 for Pituitary Tumors

Wolfgang Saeger
1   Institute of Pathology and Neuropathology of the University of Hamburg, UKE, Hamburg, Germany
,
Arend Koch
2   Institute of Neuropathology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

According to the WHO classification 2017 of Pituitary Tumors adenomas are classified not only by structure and immunostaining for pituitary hormones but also by expression of the pituitary transcription factors Pit-1, T-pit and SF-1. By these factors, three cell lineages can be identified: Pit-1 for the GH-, Prolactin- and TSH-cell lineage, T-pit for the ACTH-cell lineage, and SF-1 for the gonadotrophic cell lineage. By this principle, all GH and/or Prolactin producing and all TSH producing adenomas must be positive for Pit-1, all corticotrophic adenomas for T-pit, and all gonadotrophic for SF-1. In adenomas without expression of pituitary hormones immunostainings for the transcription factors have to be examined. If these are also negative the criteria for an endocrine inactive null cell adenoma are fulfilled. If one transcription factor is positive the corresponding cell lineage indicates a potential hormonal activity of the adenoma. So Pit-1 expressing hormone-negative adenomas can account for acromegaly, hyperprolactinemia, or TSH hyperfunction. T-pit positive hormone negative adenomas can induce Cushing’s disease, and SF-1 positive hormone negative tumors indicate gonadotrophic adenomas. Instead of the deleted atypical adenoma of the WHO classification of 2004 now (WHO classification 2017) criteria exist for the identification of aggressive adenomas with a conceivably worse prognosis. Some adenoma subtypes are described as aggressive “per se” without necessity of increased morphological signs of proliferation. All other adenoma subtypes must also be designated as aggressive if they show signs of increased proliferation (mitoses, Ki-67 index>3–5%, clinically rapid tumor growth) and invasion. By these criteria about one third of pituitary adenoma belong to the group of aggressive adenomas with potentially worse prognosis. The very rare pituitary carcinoma (0.1 % of pituitary tumors) is defined only by metastases. Many of them develop after several recurrences of Prolactin or ACTH secreting adenomas. The correlation of clinical findings and histological classification of pituitary adenomas is very important since every discrepancy has to be discussed between clinicians and pathologists. Based on data of the German Registry of Pituitary Tumors a table for examinations of correlations is shown in this review.



Publication History

Received: 05 October 2020
Received: 12 November 2020

Accepted: 13 November 2020

Article published online:
09 March 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Daly AF, Tichomirowa MA, Beckers A. The epidemiology and genetics of pituitary adenomas. Best Practice & Research Clinical Endocrinology & Metabolism 2009; 23: 543-554
    CrossrefPubMedGoogle Scholar
  • 2 Ezzat S, Asa SL, Couldwell WT. et al. The prevalence of pituitary adenomas - A systematic review. Cancer 2004; 101: 613-619
    CrossrefPubMedGoogle Scholar
  • 3 Pepe S, Korbonits M, Iacovazzo D. Germline and mosaic mutations causing pituitary tumours: genetic and molecular aspects. Journal of Endocrinology 2019; 240: R21-R45
    CrossrefPubMedGoogle Scholar
  • 4 Buurman H, Saeger W. Subclinical adenomas in postmortem pituitaries: classification and correlation to clinical data. Exper clin Endocr Metab 2006; 114: S 29 abstract P04-044
    PubMedGoogle Scholar
  • 5 Saeger W, Schmidt W. Classification and immunohistology of clinically silent adenomas in postmortem pituitaries. In: Levy E.. Advances in Pathology (anatomic and clinical). Vol. 2. 343-347 Pergamonn Press; Oxford-New York-Toronro-Sydney-Paris-Frankfurt: 1994
    Google Scholar
  • 6 Tomita T, Gates E. Pituitary adenomas and granular cell tumors - Incidence, cell type, and location of tumor in 100 pituitary glands at autopsy. Am J Clin Pathol 1999; 111: 817-825
    CrossrefPubMedGoogle Scholar
  • 7 Fontana E, Gaillard R. Epidemiology of pituitary adenoma: results of the first Swiss study. Revue Medicale Suisse 2009; 5: 2172-2174
    PubMedGoogle Scholar
  • 8 Souteiro P, Maia R, Santos-Silva R. et al. Pituitary incidentalomas in paediatric age are different from those described in adulthood. Pituitary 2019; 22: 124-128
    CrossrefPubMedGoogle Scholar
  • 9 Graffeo CS, Perry A, Link MJ. et al. Pediatric Craniopharyngiomas: A Primer for the Skull Base Surgeon. Journal of Neurological Surgery Part B-Skull Base 2018; 79: 65-80
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Gold E. Epidemiology of pituitary adenomas. Epidemiol Rev 1981; 3: 163-183
    CrossrefPubMedGoogle Scholar
  • 11 Osamura R, Lopes MBS, Grossman A. et al. Tumours of the pituitary gland. In: Lloyd R.V., Osamura R.Y., Klöppel G., Rosai J.. WHO classification of tumours of endocrine organs. Ed.4th. 11-64 Springer; Heidelberg-Berlin: 2017
    Google Scholar
  • 12 Saeger W, Buslei R. Data of the German Pituitary Tumor Registry in 2018 and 2019 according to the new WHO classification of 2017. 2020 (UnPub)
    PubMedGoogle Scholar
  • 13 Al-Dahmani K, Mohammad S, Imran F. et al. Sellar Masses: An Epidemiological Study. Canadian Journal of Neurological Sciences 2016; 43: 291-297
    CrossrefPubMedGoogle Scholar
  • 14 Obari A, Sano T, Ohyama K. et al. Clinicopathological features of growth hormone-producing pituitary adenomas: Difference among various types defined by cytokeratin distribution pattern including a transitional form. Endocr Pathol 2008; 19: 82-91
    CrossrefPubMedGoogle Scholar
  • 15 Kaptain GJ, Simmons NE, Alden TD. et al. Estrogen receptors in prolactinomas: a clinico-pathological study. Pituitary 1999; 1: 91-98
    CrossrefPubMedGoogle Scholar
  • 16 Chinezu L, Vasiljevic A, Jouanneau E. et al. Expression of somatostatin receptors, SSTR2A and SSTR5, in 108 endocrine pituitary tumors using immunohistochemical detection with new specific monoclonal antibodies. Hum Pathol 2014; 45: 71-77
    CrossrefPubMedGoogle Scholar
  • 17 Barlier A, Gunz G, Zamora AJ. et al. Prognostic and therapeutic consequences of G(s)alpha mutations in somatotroph adenomas. J Clin Endocrinol Metab 1998; 83: 1604-1610
    PubMedGoogle Scholar
  • 18 Freda PU, Chung WK, Matsuoka N. et al. Analysis of GNAS mutations in 60 growth hormone secreting pituitary tumors: Correlation with clinical and pathological characteristics and surgical outcome based on highly sensitive GH and IGF-I criteria for remission. Pituitary 2007; 10: 275-282
    CrossrefPubMedGoogle Scholar
  • 19 Landis CA, Harsh G, Lyons J. et al. Clinical characteristics of acromegalic patients whose pituitary tumors contain mutant Gs protein. J Clin Endocrinol Metab 1990; 71: 1416-1420
    CrossrefPubMedGoogle Scholar
  • 20 Horvath E, Kovacs K. Pathology of acromegaly. Neuroendocrinology 2006; 83: 161-165
    CrossrefPubMedGoogle Scholar
  • 21 Kreutzer J, Vance ML, Lopes MBS. et al. Surgical management of GH-secreting pituitary adenomas: An outcome study using modern remission criteria. Journal of Clinical Endocrinology & Metabolism 2001; 86: 4072-4077
    CrossrefPubMedGoogle Scholar
  • 22 Daly AF, Rixhon M, Adam C. et al. High prevalence of pituitary adenomas: A cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 2006; 91: 4769-4775
    CrossrefPubMedGoogle Scholar
  • 23 Mete O, Asa SL. Clinicopathological Correlations in Pituitary Adenomas. Brain Pathology 2012; 22: 443-453
    CrossrefPubMedGoogle Scholar
  • 24 Mete O, Asa SL. Therapeutic implications of accurate classification of pituitary adenomas. Semin Diagn Pathol 2013; 30: 158-164
    CrossrefPubMedGoogle Scholar
  • 25 Lipper S, Isenberg HD, Kahn LB. Calcospherites in pituitary prolactinomas. A hypothesis for their formation. Arch Pathol Lab Med 1984; 108: 31-34
    PubMedGoogle Scholar
  • 26 Saeger W, Gerigk C, Missmahl HP. et al. Amyloidablagerungen in Hypophysenadenomen. Polarisationsoptische, immunhistologische und elektronenmikroskopische Untersuchungen. Pathologe 1983; 4: 183-189
    PubMedGoogle Scholar
  • 27 Horvath E. Ultrastructural Markers in the Pathologic Diagnosis of Pituitary Adenomas. Ultrastruct Pathol 1994; 18: 171-179
    CrossrefPubMedGoogle Scholar
  • 28 Asa SL. Tumors of the pituitary gland. pp 1-210 Armed Forces Institute of Pathology; Washington,D.C: 1998
    Google Scholar
  • 29 Amlashi FG, Tritos NA. Thyrotropin-secreting pituitary adenomas: epidemiology, diagnosis, and management. Endocrine 2016; 52: 427-440
    CrossrefPubMedGoogle Scholar
  • 30 Scheithauer BW, Horvath E, Lloyd RV. et al. Pathology of pituitary adenomas and pituitary hyperplasia. In: Thapar K., Kovacs K., Scheithauer B.W., Lloyd R.V.. Diagnosis and management pituitary tumors. Ed.1. 91-154 Humana Press; Totowa,NJ: 2001
    Google Scholar
  • 31 Horvath E, Kovacs K. The adenohypophysis. In: Kovacs K., Asa S.L.. Functional endocrine pathology. 245-282 Blackwell Scientific Publ; Oxford, London, Edinburgh, Melbourne, Paris, Berlin, Vienna: 1991
    Google Scholar
  • 32 Du JY, Ji H, Jin JQ. et al. Pituitary adenoma secondary to primary hypothyroidism Two case reports. Medicine 2020; 99
    PubMedGoogle Scholar
  • 33 Fatourechi V, Gharib H, Scheithauer BW. et al. Pituitary thyrotropic adenoma associated with congenital hypothyroidism. Report of two cases. Amer J Med 1984; 76: 725-728
    CrossrefPubMedGoogle Scholar
  • 34 Lüdecke DK, Flitsch J, Knappe UJ. et al. Cushing’s disease: A surgical view. J Neurooncol 2001; 54: 151-166
    CrossrefPubMedGoogle Scholar
  • 35 Lloyd RV. Surgical pathology of the pituitary gland. pp 1-256 W.B.Saunders Comp; Philadelphia-London-Toronto-Montreal-Sydney-Tokyo: 1993
    Google Scholar
  • 36 Saeger W. Hypophyse. In: Amann K., Kain R., Klöppel G.. Urogenitale und endokrine Organe, Gelenke und Skelett. Ed.3. Aufl. 587-630 Springer; Heidelberg: 2015
    Google Scholar
  • 37 George DH, Scheithauer BW, Kovacs K. et al. Crooke’s cell adenoma of the pituitary - An aggressive variant of corticotroph adenoma. Amer J Surg Pathol 2003; 27: 1330-1336
    CrossrefPubMedGoogle Scholar
  • 38 Tanaka S, Yamamoto M, Morita M. et al. Successful reduction of ACTH secretion in a case of intractable Cushing’s disease with pituitary Crooke’s cell adenoma by combined modality therapy including temozolomide. Endocrine Journal 2019; 66: 701-708
    CrossrefPubMedGoogle Scholar
  • 39 Landolt AM, Heitz PU. Alpha-subunit-producing pituitary adenomas. Immunocytochemical and ultrastructural studies. Virchows Arch A Pathol Anat Histopath 1986; 409: 417-431
    CrossrefPubMedGoogle Scholar
  • 40 DeLellis RA, Lloyd RV, Heitz PU. Pathology and genetics: Tumours of endocrine organs (World Health Organization classification of tumours). Ed. 1. 1-311 International Agency for Research and Cancer (IARC); Lyon: 2004
    Google Scholar
  • 41 Manojlovic-Gacic E, Engstrom B, Casar-Borota O. Histopathological classification of non-functioning pituitary neuroendocrine tumors. Pituitary 2018; 21: 119-129
    CrossrefPubMedGoogle Scholar
  • 42 Almeida JP, Stephens CC, Eschbacher JM. et al. Clinical, pathologic, and imaging characteristics of pituitary null cell adenomas as defined according to the 2017 World Health Organization criteria: a case series from two pituitary centers. Pituitary 2019; 22: 514-519
    CrossrefPubMedGoogle Scholar
  • 43 Balogun JA, Monsalves E, Juraschka K. et al. Null Cell Adenomas of the Pituitary Gland: an Institutional Review of Their Clinical Imaging and Behavioral Characteristics. Endocr Pathol 2015; 26: 63-70
    CrossrefPubMedGoogle Scholar
  • 44 Nishioka H, Ito H, Hirano A. Immunohistochemical demonstration of oncocytes in nongonadotrophic pituitary adenomas. Virchows Archiv 1999; 435: 428-433
    CrossrefPubMedGoogle Scholar
  • 45 Rasul FT, Jaunmuktane Z, Khan AA. et al. Plurihormonal pituitary adenoma with concomitant adrenocorticotropic hormone (ACTH) and growth hormone (GH) secretion: a report of two cases and review of the literature. Acta Neurochirurgica 2014; 156: 141-146
    CrossrefPubMedGoogle Scholar
  • 46 Horvath E, Kovacs K, Smyth HS. et al. Silent adenoma subtype 3 of the pituitary - Immunohistochemical and ultrastructural classification: A review of 29 cases. Ultrastruct Pathol 2005; 29: 511-524
    CrossrefPubMedGoogle Scholar
  • 47 Erickson D, Scheithauer B, Atkinson J. et al. Silent subtype 3 pituitary adenoma: a clinicopathologic analysis of the Mayo Clinic experience. Clin Endorin 2009; 71: 92-99
    CrossrefPubMedGoogle Scholar
  • 48 Saeger W, Lüdecke DK, Buchfelder M. et al. Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. Eur J Endocrinol 2007; 156: 205-217
    CrossrefPubMedGoogle Scholar
  • 49 Zada G, Woodmansee WW, Ramkissoon S. et al. Atypical pituitary adenomas: incidence, clinical characteristics, and implications Clinical article. J Neurosurg 2011; 114: 336-344
    CrossrefPubMedGoogle Scholar
  • 50 Miermeister CP, Petersenn S, Buchfelder M. et al. Histological criteria for atypical adenomas: data from German Pituitary Tumor Registry suggest modifications. acta neuropath communications 2015; 3: 50
    CrossrefPubMedGoogle Scholar
  • 51 Asioli S, Righi A, Iommi M. et al. Validation of a clinicopathological score for the prediction of post-surgical evolution of pituitary adenoma: retrospective analysis on 566 patients from a tertiary care centre. Eur J Endocrin 2019; 180: 127-134
    CrossrefPubMedGoogle Scholar
  • 52 Raverot G, Dantony E, Beauvy J. et al. Risk of Recurrence in Pituitary Neuroendocrine Tumors: A Prospective Study Using a Five-Tiered Classification. Journal of Clinical Endocrinology & Metabolism 2017; 102: 3368-3374
    CrossrefPubMedGoogle Scholar
  • 53 Hornyak M, Couldwell WT. Multimodality Treatment for Invasive Pituitary Adenomas. Postgraduate Medicine 2009; 121: 168-176
    CrossrefPubMedGoogle Scholar
  • 54 Priola SM, Esposito F, Cannavo S. et al. Aggressive Pituitary Adenomas: The Dark Side of the Moon. World Neurosurgery 2017; 97: 140-155
    CrossrefPubMedGoogle Scholar
  • 55 Di Ieva A, Rotondo F, Syro LV. et al. Aggressive pituitary adenomas-diagnosis and emerging treatments. Nature Reviews Endocrinology 2014; 10: 423-435
    CrossrefPubMedGoogle Scholar
  • 56 Roncaroli F, Scheithauer BW, Horvath E. et al. Silent subtype 3 carcinoma of the pituitary: a case report. Neuropathology and Applied Neurobiology 2010; 36: 90-94
    CrossrefPubMedGoogle Scholar
  • 57 Raverot G, Burman P, McCormack A. et al. European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrin 2018; 178: G1-G24
    CrossrefPubMedGoogle Scholar
  • 58 Fakih H, Beel BC, Shychuk A. et al. Bilateral adrenal hemorrhage. Intensive Care Medicine 2017; 43: 447-448
    CrossrefPubMedGoogle Scholar
  • 59 McCormack AI, McDonald KL, Gill AJ. et al. Low O(6)-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours. Clin Endorin 2009; 71: 226-233
    CrossrefPubMedGoogle Scholar
  • 60 Salehi F, Scheithauer BW, Kovacs K. et al. O-6-Methylguanine-DNA Methyltransferase (MGMT) Immunohistochemical Expression in Pituitary Corticotroph Adenomas. Neurosurgery 2012; 70: 491-496
    CrossrefPubMedGoogle Scholar
  • 61 Sav A, Rotondo F, Syro LV. et al. Invasive, Atypical and Aggressive Pituitary Adenomas and Carcinomas. Endocrinology and Metabolism Clinics of North America 2015; 44: 99-+
    CrossrefPubMedGoogle Scholar
  • 62 Knappe UJ, Jaspers C, Buschsieweke D. et al. Ectopic Adrenocorticotropic Hormone-Secreting Pituitary Adenomas: An Underestimated Entity. Neurosurgery 2017; 80: 525-533
    CrossrefPubMedGoogle Scholar
  • 63 Randall RV. Pituitary adenomas associated with hyperprolactinemia: a clinical and immunohistochemical study of 97 patients operated on transsphenoidally. 1985
    PubMedGoogle Scholar
  • 64 Hebert L, Gervais F. apo-SAA1/apo-SAA2 isotype ratios during casein- and amyloid- enhancing-factor-induced secondary amyloidosis in A/J and C57BL/6J mice mice. Scand J Immunol 1990; 31: 167-173
    CrossrefPubMedGoogle Scholar
  • 65 Neou M, Villa C, Armignacco R. et al. Pangenomic Classification of Pituitary Neuroendocrine Tumors. Cancer Cell 2020; 37: 1-12
    CrossrefPubMedGoogle Scholar